{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T16:54:48Z","timestamp":1794848088342,"version":"4.9.1"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PC190482"],"award-info":[{"award-number":["PC190482"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The abnormal deposition of \u03b1-synuclein (\u03b1-syn) and neuroinflammation are key features of synucleinopathies. We recently demonstrated that leucine-rich repeat kinase 2 (LRRK2) and nuclear factor of activated T cells 1 (NFAT1) modulate the neurotoxic inflammation in synucleinopathies mediated by microglia. Therefore, we hypothesized that targeting NFAT1 might ameliorate the microglial neurotoxicity in synucleinopathies. Here we utilized 11R-VIVIT, an NFAT1 inhibitory peptide, in in vivo, ex vivo and in vitro synucleinopathy models to evaluate the effects of NFAT1 inhibition to test this hypothesis. The microglia in synucleinopathy mouse models become excessively activated due to chronic disease conditions, thereby increasing the expressions of proinflammatory cytokines in these cells and decreasing the expressions of genes associated with microglial mobility and phagocytosis, strongly associated with neurodegeneration and pathogenic \u03b1-syn deposition. However, we observed that the inhibition of NFAT1 decreased the microglial neuroinflammation, thereby ameliorating neurodegeneration and \u03b1-syn neuropathology in vivo. Furthermore, the comprehensive in vivo transcriptomic analysis of the microglia revealed that the inhibition of NFAT1 restored their mobility and phagocytic abilities via upregulations of related genes. Our study proposes that the inhibition of NFAT1 redirects the excessively activated microglia to active healthy microglia, thereby reducing synucleinopathy neurotoxicity.<\/jats:p>","DOI":"10.1038\/s12276-025-01564-4","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T05:54:41Z","timestamp":1763358881000},"page":"2588-2607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Redirecting microglia phenotype via inhibition of NFAT1 ameliorates deficits in mouse model of synucleinopathies"],"prefix":"10.1038","volume":"57","author":[{"given":"Michiyo","family":"Iba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6605-8761","authenticated-orcid":false,"given":"Yeon-Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7237-7574","authenticated-orcid":false,"given":"Liam","family":"Horan-Portelance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Landeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3513-1783","authenticated-orcid":false,"given":"Sungyong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9936-8195","authenticated-orcid":false,"given":"Changyoun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"1564_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrneurol.2013.275","volume":"10","author":"HJ Lee","year":"2014","unstructured":"Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular \u03b1-synuclein\u2014a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92\u201398 (2014).","journal-title":"Nat. Rev. Neurol."},{"key":"1564_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00401-011-0833-z","volume":"121","author":"L Fellner","year":"2011","unstructured":"Fellner, L., Jellinger, K. A., Wenning, G. K. & Stefanova, N. Glial dysfunction in the pathogenesis of \u03b1-synucleinopathies: emerging concepts. Acta Neuropathol. 121, 675\u2013693 (2011).","journal-title":"Acta Neuropathol."},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1471-4159.2008.05612.x","volume":"107","author":"C Kim","year":"2008","unstructured":"Kim, C. & Lee, S. J. Controlling the mass action of \u03b1-synuclein in Parkinson\u2019s disease. J. Neurochem. 107, 303\u2013316 (2008).","journal-title":"J. Neurochem."},{"key":"1564_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5607\/en.2016.25.3.113","volume":"25","author":"C Kim","year":"2016","unstructured":"Kim, C., Lee, H. J., Masliah, E. & Lee, S. J. Non-cell-autonomous neurotoxicity of \u03b1-synuclein through microglial Toll-like receptor 2. Exp. Neurobiol. 25, 113\u2013119 (2016).","journal-title":"Exp. Neurobiol."},{"key":"1564_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.pneurobio.2018.06.010","volume":"169","author":"S Lim","year":"2018","unstructured":"Lim, S., Kim, H. J., Kim, D. K. & Lee, S. J. Non-cell-autonomous actions of \u03b1-synuclein: implications in glial synucleinopathies. Prog. Neurobiol. 169, 158\u2013171 (2018).","journal-title":"Prog. Neurobiol."},{"key":"1564_CR6","doi-asserted-by":"publisher","first-page":"13010","DOI":"10.1073\/pnas.0903691106","volume":"106","author":"P Desplats","year":"2009","unstructured":"Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of \u03b1-synuclein. Proc. Natl Acad. Sci. USA 106, 13010\u201313015 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1564_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.23455","volume":"26","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M. & Stevens, C. H. Glia: initiators and progressors of pathology in Parkinson\u2019s disease. Mov. Disord. 26, 6\u201317 (2011).","journal-title":"Mov. Disord."},{"key":"1564_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2534","volume":"4","author":"C Kim","year":"2013","unstructured":"Kim, C. et al. Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).","journal-title":"Nat. Commun."},{"key":"1564_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.celrep.2015.09.044","volume":"13","author":"C Kim","year":"2015","unstructured":"Kim, C. et al. Antagonizing neuronal Toll-like receptor 2 prevents synucleinopathy by activating autophagy. Cell Rep. 13, 771\u2013782 (2015).","journal-title":"Cell Rep."},{"key":"1564_CR10","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fnins.2016.00408","volume":"10","author":"M Ingelsson","year":"2016","unstructured":"Ingelsson, M. \u03b1-synuclein oligomers-neurotoxic molecules in Parkinson\u2019s disease and other Lewy body disorders. Front. Neurosci. 10, 408 (2016).","journal-title":"Front. Neurosci."},{"key":"1564_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.toxlet.2016.11.002","volume":"265","author":"QS Zhang","year":"2017","unstructured":"Zhang, Q. S., Heng, Y., Yuan, Y. H. & Chen, N. H. Pathological \u03b1-synuclein exacerbates the progression of Parkinson\u2019s disease through microglial activation. Toxicol. Lett. 265, 30\u201337 (2017).","journal-title":"Toxicol. Lett."},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.5607\/en.2019.28.5.547","volume":"28","author":"S Kwon","year":"2019","unstructured":"Kwon, S., Iba, M., Masliah, E. & Kim, C. Targeting microglial and neuronal Toll-like receptor 2 in synucleinopathies. Exp. Neurobiol. 28, 547\u2013553 (2019).","journal-title":"Exp. Neurobiol."},{"key":"1564_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2012.00079","volume":"3","author":"L Oliveira-Nascimento","year":"2012","unstructured":"Oliveira-Nascimento, L., Massari, P. & Wetzler, L. M. The tole of TLR2 in infection and immunity. Front. Immunol 3, 1\u201317 (2012).","journal-title":"Front. Immunol"},{"key":"1564_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2015.12.005","volume":"158","author":"Y Wang","year":"2016","unstructured":"Wang, Y., Song, E., Bai, B. & Vanhoutte, P. M. Toll-like receptors mediating vascular malfunction: lessons from receptor subtypes. Pharm. Ther. 158, 91\u2013100 (2016).","journal-title":"Pharm. Ther."},{"key":"1564_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.str.2011.02.004","volume":"19","author":"I Botos","year":"2011","unstructured":"Botos, I., Segal, D. M. & Davies, D. R. The structural biology of Toll-like receptors. Structure 19, 447\u2013459 (2011).","journal-title":"Structure"},{"key":"1564_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","volume":"5","author":"T Kawasaki","year":"2014","unstructured":"Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 5, 461 (2014).","journal-title":"Front. Immunol."},{"key":"1564_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12016-013-8402-y","volume":"47","author":"Y Liu","year":"2014","unstructured":"Liu, Y., Yin, H., Zhao, M. & Lu, Q. TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clin. Rev. Allergy Immunol. 47, 136\u2013147 (2014).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"1564_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/1389203711314010006","volume":"14","author":"H Lee","year":"2013","unstructured":"Lee, H., Lee, S., Cho, I. H. & Lee, S. J. Toll-like receptors: sensor molecules for detecting damage to the nervous system. Curr. Protein Pept. Sci. 14, 33\u201342 (2013).","journal-title":"Curr. Protein Pept. Sci."},{"key":"1564_CR19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neulet.2017.07.014","volume":"656","author":"X Li","year":"2017","unstructured":"Li, X., Xue, L., Sun, J., Sun, Y. & Xie, A. Single nucleotide polymorphisms in the toll-like receptor 2 (TLR2) gene are associated with sporadic Parkinson\u2019s disease in the north-eastern Han Chinese population. Neurosci. Lett. 656, 72\u201376 (2017).","journal-title":"Neurosci. Lett."},{"key":"1564_CR20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10072-012-1106-x","volume":"34","author":"K Kalinderi","year":"2013","unstructured":"Kalinderi, K., Bostantjopoulou, S., Katsarou, Z. & Fidani, L. TLR9 \u22121237 T\/C and TLR2 \u2212194 to \u2212174 del polymorphisms and the risk of Parkinson\u2019s disease in the Greek population: a pilot study. Neurol. Sci. 34, 679\u2013682 (2013).","journal-title":"Neurol. Sci."},{"key":"1564_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-136","volume":"8","author":"JT Yu","year":"2011","unstructured":"Yu, J. T., Mou, S. M., Wang, L. Z., Mao, C. X. & Tan, L. Toll-like receptor 2 \u2212196 to \u2212174 del polymorphism influences the susceptibility of Han Chinese people to Alzheimer\u2019s disease. J. Neuroinflammation 8, 136 (2011).","journal-title":"J. Neuroinflammation"},{"key":"1564_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12017-015-8376-4","volume":"18","author":"M Rezazadeh","year":"2016","unstructured":"Rezazadeh, M. et al. Genetic factors affecting late-onset Alzheimer\u2019s disease susceptibility. Neuromolecular Med. 18, 37\u201349 (2016).","journal-title":"Neuromolecular Med."},{"key":"1564_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbi.2016.07.143","volume":"58","author":"CL McDonald","year":"2016","unstructured":"McDonald, C. L. et al. Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer\u2019s disease. Brain Behav. Immun. 58, 191\u2013200 (2016).","journal-title":"Brain Behav. Immun."},{"key":"1564_CR24","doi-asserted-by":"publisher","first-page":"pyu103","DOI":"10.1093\/ijnp\/pyu103","volume":"18","author":"J Drouin-Ouellet","year":"2015","unstructured":"Drouin-Ouellet, J. et al. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. Int. J. Neuropsychopharmacol 18, pyu103, https:\/\/doi.org\/10.1093\/ijnp\/pyu103 (2015).","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"1564_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-5960-2-1","volume":"2","author":"KJ Doorn","year":"2014","unstructured":"Doorn, K. J. et al. Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson\u2019s disease patients. Acta Neuropathol. Commun 2, 1\u201317 (2014).","journal-title":"Acta Neuropathol. Commun"},{"key":"1564_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00401-016-1648-8","volume":"133","author":"N Dzamko","year":"2017","unstructured":"Dzamko, N. et al. Toll-like receptor 2 is increased in neurons in Parkinsonas disease brain and may contribute to \u00e0-synuclein pathology. Acta Neuropathol. 133, 303\u2013319 (2017).","journal-title":"Acta Neuropathol."},{"key":"1564_CR27","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1523\/JNEUROSCI.5227-07.2008","volume":"28","author":"JI Luoma","year":"2008","unstructured":"Luoma, J. I. & Zirpel, L. Deafferentation-induced activation of NFAT (nuclear factor of activated T-cells) in cochlear nucleus neurons during a developmental critical period: a role for NFATc4-dependent apoptosis in the CNS. J. Neurosci. 28, 3159\u20133169 (2008).","journal-title":"J. Neurosci."},{"key":"1564_CR28","doi-asserted-by":"publisher","first-page":"e0139652","DOI":"10.1371\/journal.pone.0139652","volume":"10","author":"S Stalmans","year":"2015","unstructured":"Stalmans, S. et al. Cell-penetrating peptides selectively cross the blood\u2013brain barrier in vivo. PLoS ONE 10, e0139652 (2015).","journal-title":"PLoS ONE"},{"key":"1564_CR29","doi-asserted-by":"publisher","first-page":"eaay0399","DOI":"10.1126\/scitranslmed.aay0399","volume":"12","author":"C Kim","year":"2020","unstructured":"Kim, C. et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci. Transl. Med 12, eaay0399, https:\/\/doi.org\/10.1126\/scitranslmed.aay0399 (2020).","journal-title":"Sci. Transl. Med"},{"key":"1564_CR30","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13311-012-0104-2","volume":"9","author":"MF Chesselet","year":"2012","unstructured":"Chesselet, M. F. et al. A progressive mouse model of Parkinson\u2019s disease: the Thy1-aSyn (\u2019line 61\u2019) mice. Neurotherapeutics 9, 297\u2013314 (2012).","journal-title":"Neurotherapeutics"},{"key":"1564_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","volume":"13","author":"C Kim","year":"2018","unstructured":"Kim, C. et al. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating \u03b1-synuclein transmission and neuroinflammation. Mol. Neurodegener. 13, 43 (2018).","journal-title":"Mol. Neurodegener."},{"key":"1564_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12667","volume":"47","author":"S Al-Sarraj","year":"2021","unstructured":"Al-Sarraj, S. et al. Invited review: the spectrum of neuropathology in COVID-19. Neuropathol. Appl. Neurobiol. 47, 3\u201316 (2021).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"1564_CR33","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.xpro.2020.100035","volume":"1","author":"EA Bordt","year":"2020","unstructured":"Bordt, E. A. et al. Isolation of microglia from mouse or human tissue. STAR Protoc 1, 100035, https:\/\/doi.org\/10.1016\/j.xpro.2020.100035 (2020).","journal-title":"STAR Protoc"},{"key":"1564_CR34","unstructured":"Andrews, S. FastQC. Babraham Bioinformatics https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/ (Babraham Bioinformatics, 2010)."},{"key":"1564_CR35","unstructured":"Krueger, F. Trim Galore. Babraham Bioinformatics https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/trim_galore\/ (Babraham Bioinformatics, 2012)."},{"key":"1564_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1564_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 12, 323 (2011).","journal-title":"BMC Bioinform."},{"key":"1564_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"1564_CR39","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1074\/jbc.M109.081125","volume":"285","author":"HJ Lee","year":"2010","unstructured":"Lee, H. J. et al. Direct transfer of \u03b1-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem. 285, 9262\u20139272 (2010).","journal-title":"J. Biol. Chem."},{"key":"1564_CR40","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman, B. T. et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update).Nucleic Acids Res 50, W216\u2013W221 (2022).","journal-title":"Nucleic Acids Res"},{"key":"1564_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23111-1","volume":"12","author":"A Grubman","year":"2021","unstructured":"Grubman, A. et al. Transcriptional signature in microglia associated with Abeta plaque phagocytosis. Nat. Commun. 12, 3015 (2021).","journal-title":"Nat. Commun."},{"key":"1564_CR42","doi-asserted-by":"publisher","first-page":"e13606","DOI":"10.1111\/acel.13606","volume":"21","author":"T Patel","year":"2022","unstructured":"Patel, T. et al. Transcriptional landscape of human microglia implicates age, sex, and APOE-related immunometabolic pathway perturbations. Aging Cell 21, e13606 (2022).","journal-title":"Aging Cell"},{"key":"1564_CR43","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/glia.23137","volume":"65","author":"P Matsye","year":"2017","unstructured":"Matsye, P. et al. HuR promotes the molecular signature and phenotype of activated microglia: implications for amyotrophic lateral sclerosis and other neurodegenerative diseases. Glia 65, 945\u2013963 (2017).","journal-title":"Glia"},{"key":"1564_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fnins.2019.00002","volume":"13","author":"S Mukherjee","year":"2019","unstructured":"Mukherjee, S., Klaus, C., Pricop-Jeckstadt, M., Miller, J. A. & Struebing, F. L. A microglial signature directing human aging and neurodegeneration-related gene networks. Front. Neurosci. 13, 2 (2019).","journal-title":"Front. Neurosci."},{"key":"1564_CR45","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1564_CR46","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"1564_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-10-r93","volume":"7","author":"DM Levine","year":"2006","unstructured":"Levine, D. M. et al. Pathway and gene-set activation measurement from mRNA expression data: the tissue distribution of human pathways. Genome Biol. 7, R93 (2006).","journal-title":"Genome Biol."},{"key":"1564_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.35","volume":"4","author":"A Miyashita","year":"2014","unstructured":"Miyashita, A. et al. Genes associated with the progression of neurofibrillary tangles in Alzheimer\u2019s disease. Transl. Psychiatry 4, e396 (2014).","journal-title":"Transl. Psychiatry"},{"key":"1564_CR49","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s12276-021-00562-6","volume":"53","author":"C Kim","year":"2021","unstructured":"Kim, C. et al. Effects of innate immune receptor stimulation on extracellular \u03b1-synuclein uptake and degradation by brain resident cells. Exp. Mol. Med. 53, 281\u2013290 (2021).","journal-title":"Exp. Mol. Med."},{"key":"1564_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.6","volume":"46","author":"C Kim","year":"2014","unstructured":"Kim, C. et al. \u03b21-integrin-dependent migration of microglia in response to neuron-released \u03b1-synuclein. Exp. Mol. Med. 46, e91 (2014).","journal-title":"Exp. Mol. Med."},{"key":"1564_CR51","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","volume":"47","author":"IG McKeith","year":"1996","unstructured":"McKeith, I. G. et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47, 1113\u20131124 (1996).","journal-title":"Neurology"},{"key":"1564_CR52","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/S0092-8674(02)00699-2","volume":"109","author":"GR Crabtree","year":"2002","unstructured":"Crabtree, G. R. & Olson, E. N. NFAT signaling: choreographing the social lives of cells. Cell 109, S67\u2013S79 (2002).","journal-title":"Cell"},{"key":"1564_CR53","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri2818","volume":"10","author":"MR Muller","year":"2010","unstructured":"Muller, M. R. & Rao, A. NFAT, immunity and cancer: a transcription factor comes of age. Nat. Rev. Immunol. 10, 645\u2013656 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"1564_CR54","doi-asserted-by":"publisher","first-page":"eabq6089","DOI":"10.1126\/scitranslmed.abq6089","volume":"15","author":"M Iba","year":"2023","unstructured":"Iba, M. et al. Inhibition of p38\u03b1 MAPK restores neuronal p38\u03b3 MAPK and ameliorates synaptic degeneration in a mouse model of DLB\/PD. Sci. Transl. Med. 15, eabq6089 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1564_CR55","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nri1632","volume":"5","author":"F Macian","year":"2005","unstructured":"Macian, F. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5, 472\u2013484 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"1564_CR56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2020.00195","volume":"11","author":"YJ Park","year":"2020","unstructured":"Park, Y. J., Yoo, S. A., Kim, M. & Kim, W. U. The role of calcium\u2013calcineurin\u2013NFAT signaling pathway in health and autoimmune diseases. Front. Immunol. 11, 195 (2020).","journal-title":"Front. Immunol."},{"key":"1564_CR57","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.bbrc.2008.05.045","volume":"372","author":"HJ Lee","year":"2008","unstructured":"Lee, H. J., Suk, J. E., Bae, E. J. & Lee, S. J. Clearance and deposition of extracellular \u03b1-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 372, 423\u2013428 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1564_CR58","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","volume":"110","author":"RC Paolicelli","year":"2022","unstructured":"Paolicelli, R. C. et al. Microglia states and nomenclature: a field at its crossroads. Neuron 110, 3458\u20133483 (2022).","journal-title":"Neuron"},{"key":"1564_CR59","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.3260404","volume":"241","author":"JP Shaw","year":"1988","unstructured":"Shaw, J. P. et al. Identification of a putative regulator of early T cell activation genes. Science 241, 202\u2013205 (1988).","journal-title":"Science"},{"key":"1564_CR60","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1101\/sqb.1999.64.527","volume":"64","author":"L Chen","year":"1999","unstructured":"Chen, L., Rao, A. & Harrison, S. C. Signal integration by transcription-factor assemblies: interactions of NF-AT1 and AP-1 on the IL-2 promoter. Cold Spring Harb. Symp. Quant. Biol. 64, 527\u2013531 (1999).","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"1564_CR61","first-page":"316","volume":"73","author":"DJ Henderson","year":"1991","unstructured":"Henderson, D. J., Naya, I., Bundick, R. V., Smith, G. M. & Schmidt, J. A. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunology 73, 316\u2013321 (1991).","journal-title":"Immunology"},{"key":"1564_CR62","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.3389\/fimmu.2018.02747","volume":"9","author":"JU Lee","year":"2018","unstructured":"Lee, J. U., Kim, L. K. & Choi, J. M. Revisiting the concept of targeting NFAT to control T cell immunity and autoimmune diseases. Front. Immunol. 9, 2747 (2018).","journal-title":"Front. Immunol."},{"key":"1564_CR63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/nrc2735","volume":"9","author":"M Mancini","year":"2009","unstructured":"Mancini, M. & Toker, A. NFAT proteins: emerging roles in cancer progression. Nat. Rev. Cancer 9, 810\u2013820 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"1564_CR64","doi-asserted-by":"publisher","first-page":"260","DOI":"10.12688\/f1000research.13426.1","volume":"7","author":"M Vaeth","year":"2018","unstructured":"Vaeth, M. & Feske, S. NFAT control of immune function: new frontiers for an abiding trooper. F1000Res 7, 260 (2018).","journal-title":"F1000Res"},{"key":"1564_CR65","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nri2152","volume":"7","author":"S Feske","year":"2007","unstructured":"Feske, S. Calcium signalling in lymphocyte activation and disease. Nat. Rev. Immunol. 7, 690\u2013702 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"1564_CR66","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/ni.2113","volume":"12","author":"Z Liu","year":"2011","unstructured":"Liu, Z. et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 12, 1063\u20131070 (2011).","journal-title":"Nat. Immunol."},{"key":"1564_CR67","doi-asserted-by":"publisher","first-page":"113775","DOI":"10.1016\/j.fct.2023.113775","volume":"176","author":"X Yan","year":"2023","unstructured":"Yan, X. et al. Acrylamide induces the activation of BV2 microglial cells through TLR2\/4-mediated LRRK2-NFATc2 signaling cascade. Food Chem. Toxicol. 176, 113775 (2023).","journal-title":"Food Chem. Toxicol."},{"key":"1564_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18755-4","volume":"11","author":"V Panagiotakopoulou","year":"2020","unstructured":"Panagiotakopoulou, V. et al. Interferon-\u03b3 signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells. Nat. Commun. 11, 5163 (2020).","journal-title":"Nat. Commun."},{"key":"1564_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13311-022-01338-0","volume":"20","author":"F Richter","year":"2023","unstructured":"Richter, F., Stanojlovic, M., Kaufer, C., Gericke, B. & Feja, M. A mouse model to test novel therapeutics for Parkinson\u2019s disease: an update on the Thy1-aSyn (\u2018line 61\u2019) mice. Neurotherapeutics 20, 97\u2013116 (2023).","journal-title":"Neurotherapeutics"},{"key":"1564_CR70","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jneumeth.2010.03.026","volume":"189","author":"H Shiotsuki","year":"2010","unstructured":"Shiotsuki, H. et al. A rotarod test for evaluation of motor skill learning. J. Neurosci. Methods 189, 180\u2013185 (2010).","journal-title":"J. Neurosci. Methods"},{"key":"1564_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-2-14","volume":"2","author":"E Croisier","year":"2005","unstructured":"Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K. & Graeber, M. B. Microglial inflammation in the parkinsonian substantia nigra: relationship to \u03b1-synuclein deposition. J. Neuroinflammation 2, 14 (2005).","journal-title":"J. Neuroinflammation"},{"key":"1564_CR72","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fnmol.2018.00144","volume":"11","author":"E Janda","year":"2018","unstructured":"Janda, E., Boi, L. & Carta, A. R. Microglial phagocytosis and its regulation: a therapeutic target in Parkinson\u2019s disease?. Front. Mol. Neurosci. 11, 144 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"1564_CR73","doi-asserted-by":"publisher","first-page":"10558","DOI":"10.1523\/JNEUROSCI.1799-06.2006","volume":"26","author":"SA Austin","year":"2006","unstructured":"Austin, S. A., Floden, A. M., Murphy, E. J. & Combs, C. K. \u03b1-synuclein expression modulates microglial activation phenotype. J. Neurosci. 26, 10558\u201310563 (2006).","journal-title":"J. Neurosci."},{"key":"1564_CR74","doi-asserted-by":"publisher","first-page":"e71634","DOI":"10.1371\/journal.pone.0071634","volume":"8","author":"SJ Gardai","year":"2013","unstructured":"Gardai, S. J. et al. Elevated \u03b1-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson\u2019s disease. PLoS ONE 8, e71634 (2013).","journal-title":"PLoS ONE"},{"key":"1564_CR75","doi-asserted-by":"publisher","first-page":"e8784","DOI":"10.1371\/journal.pone.0008784","volume":"5","author":"V Sanchez-Guajardo","year":"2010","unstructured":"Sanchez-Guajardo, V., Febbraro, F., Kirik, D. & Romero-Ramos, M. Microglia acquire distinct activation profiles depending on the degree of \u03b1-synuclein neuropathology in a rAAV based model of Parkinson\u2019s disease. PLoS ONE 5, e8784 (2010).","journal-title":"PLoS ONE"},{"key":"1564_CR76","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.3390\/cells10092236","volume":"10","author":"J Lier","year":"2021","unstructured":"Lier, J., Streit, W. J. & Bechmann, I. Beyond activation: characterizing microglial functional phenotypes. Cells 10, 2236, https:\/\/doi.org\/10.3390\/cells10092236 (2021).","journal-title":"Cells"},{"key":"1564_CR77","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3389\/fncel.2018.00215","volume":"12","author":"S Lively","year":"2018","unstructured":"Lively, S. & Schlichter, L. C. Microglia responses to pro-inflammatory stimuli (LPS, IFN\u03b3+TNF\u03b1) and reprogramming by resolving cytokines (IL-4, IL-10). Front. Cell. Neurosci. 12, 215 (2018).","journal-title":"Front. Cell. Neurosci."},{"key":"1564_CR78","doi-asserted-by":"publisher","first-page":"105696","DOI":"10.1016\/j.nbd.2022.105696","volume":"168","author":"R Domingues","year":"2022","unstructured":"Domingues, R. et al. Extracellular \u03b1-synuclein: sensors, receptors, and responses. Neurobiol. Dis. 168, 105696 (2022).","journal-title":"Neurobiol. Dis."},{"key":"1564_CR79","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.ajpath.2011.04.013","volume":"179","author":"N Stefanova","year":"2011","unstructured":"Stefanova, N. et al. Toll-like receptor 4 promotes \u03b1-synuclein clearance and survival of nigral dopaminergic neurons. Am. J. Pathol. 179, 954\u2013963 (2011).","journal-title":"Am. J. Pathol."},{"key":"1564_CR80","doi-asserted-by":"publisher","first-page":"aah3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X Mao","year":"2016","unstructured":"Mao, X. et al. Pathological \u00e0-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, aah3374, https:\/\/doi.org\/10.1126\/science.aah3374 (2016).","journal-title":"Science"},{"key":"1564_CR81","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mcn.2015.03.018","volume":"68","author":"P Brun","year":"2015","unstructured":"Brun, P. et al. Toll like receptor-2 regulates production of glial-derived neurotrophic factors in murine intestinal smooth muscle cells. Mol. Cell. Neurosci. 68, 24\u201335 (2015).","journal-title":"Mol. Cell. Neurosci."},{"key":"1564_CR82","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1053\/j.gastro.2013.08.047","volume":"145","author":"P Brun","year":"2013","unstructured":"Brun, P. et al. Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology 145, 1323\u20131333 (2013).","journal-title":"Gastroenterology"},{"key":"1564_CR83","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3389\/fimmu.2019.01043","volume":"10","author":"EC Dresselhaus","year":"2019","unstructured":"Dresselhaus, E. C. & Meffert, M. K. Cellular specificity of NF-\u03baB Function in the nervous system. Front. Immunol. 10, 1043 (2019).","journal-title":"Front. Immunol."},{"key":"1564_CR84","first-page":"63","volume":"3","author":"K Heese","year":"2006","unstructured":"Heese, K., Inoue, N. & Sawada, T. NF-\u03baB regulates B-cell-derived nerve growth factor expression. Cell. Mol. Immunol. 3, 63\u201366 (2006).","journal-title":"Cell. Mol. Immunol."},{"key":"1564_CR85","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.3390\/ijms22052725","volume":"22","author":"N Kitamura","year":"2021","unstructured":"Kitamura, N. & Kaminuma, O. Isoform-selective NFAT inhibitor: potential usefulness and development. Int. J. Mol. Sci 22, 2725, https:\/\/doi.org\/10.3390\/ijms22052725 (2021).","journal-title":"Int. J. Mol. Sci"},{"key":"1564_CR86","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S1074-7613(00)80188-0","volume":"12","author":"A Kiani","year":"2000","unstructured":"Kiani, A., Rao, A. & Aramburu, J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 12, 359\u2013372 (2000).","journal-title":"Immunity"},{"key":"1564_CR87","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/17401","volume":"397","author":"M Hojo","year":"1999","unstructured":"Hojo, M. et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397, 530\u2013534 (1999).","journal-title":"Nature"},{"key":"1564_CR88","first-page":"3105","volume":"23","author":"JJ Fung","year":"1991","unstructured":"Fung, J. J. et al. Adverse effects associated with the use of FK 506. Transplant. Proc. 23, 3105\u20133108 (1991).","journal-title":"Transplant. Proc."},{"key":"1564_CR89","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1126\/science.285.5436.2129","volume":"285","author":"J Aramburu","year":"1999","unstructured":"Aramburu, J. et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 285, 2129\u20132133 (1999).","journal-title":"Science"},{"key":"1564_CR90","doi-asserted-by":"publisher","first-page":"424","DOI":"10.2337\/db18-0870","volume":"69","author":"E Garcia-Vaz","year":"2020","unstructured":"Garcia-Vaz, E. et al. Inhibition of NFAT signaling restores microvascular endothelial function in diabetic mice. Diabetes 69, 424\u2013435 (2020).","journal-title":"Diabetes"},{"key":"1564_CR91","doi-asserted-by":"publisher","first-page":"7020","DOI":"10.1167\/iovs.13-12183","volume":"54","author":"CA Bretz","year":"2013","unstructured":"Bretz, C. A., Savage, S., Capozzi, M. & Penn, J. S. The role of the NFAT signaling pathway in retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 54, 7020\u20137027 (2013).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1564_CR92","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1007\/s12035-021-02347-4","volume":"58","author":"M Norouzi","year":"2021","unstructured":"Norouzi, M., Miar, P., Norouzi, S. & Nikpour, P. Nervous system involvement in COVID-19: a review of the current knowledge. Mol. Neurobiol. 58, 3561\u20133574 (2021).","journal-title":"Mol. Neurobiol."},{"key":"1564_CR93","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1747-0285.2006.00360.x","volume":"67","author":"M Kuriyama","year":"2006","unstructured":"Kuriyama, M. et al. A cell-permeable NFAT inhibitor peptide prevents pressure-overload cardiac hypertrophy. Chem. Biol. Drug Des. 67, 238\u2013243 (2006).","journal-title":"Chem. Biol. Drug Des."},{"key":"1564_CR94","doi-asserted-by":"publisher","first-page":"e34172","DOI":"10.1371\/journal.pone.0034172","volume":"7","author":"HZ Elloumi","year":"2012","unstructured":"Elloumi, H. Z. et al. A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitis. PLoS ONE 7, e34172 (2012).","journal-title":"PLoS ONE"},{"key":"1564_CR95","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.imlet.2012.01.016","volume":"143","author":"JM Choi","year":"2012","unstructured":"Choi, J. M., Sohn, J. H., Park, T. Y., Park, J. W. & Lee, S. K. Cell permeable NFAT inhibitory peptide Sim-2-VIVIT inhibits T-cell activation and alleviates allergic airway inflammation and hyper-responsiveness. Immunol. Lett. 143, 170\u2013176 (2012).","journal-title":"Immunol. Lett."},{"key":"1564_CR96","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/bph.12292","volume":"170","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db\/db mice. Br. J. Pharm. 170, 426\u2013439 (2013).","journal-title":"Br. J. Pharm."},{"key":"1564_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/srep19453","volume":"6","author":"HK Kwon","year":"2016","unstructured":"Kwon, H. K. et al. Transcription factor NFAT1 controls allergic contact hypersensitivity through regulation of activation induced cell death program. Sci. Rep. 6, 19453 (2016).","journal-title":"Sci. Rep."},{"key":"1564_CR98","first-page":"245","volume":"7","author":"P Faucher","year":"2015","unstructured":"Faucher, P., Mons, N., Micheau, J., Louis, C. & Beracochea, D. J. Hippocampal injections of oligomeric amyloid \u03b2-peptide (1\u201342) induce selective working memory deficits and long-lasting alterations of ERK signaling pathway. Front. Aging Neurosci. 7, 245 (2015).","journal-title":"Front. Aging Neurosci."},{"key":"1564_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/srep15032","volume":"5","author":"Y Wu","year":"2015","unstructured":"Wu, Y. et al. Intraperitoneal administration of a novel TAT-BDNF peptide ameliorates cognitive impairments via modulating multiple pathways in two Alzheimer\u2019s rodent models. Sci. Rep. 5, 15032 (2015).","journal-title":"Sci. Rep."},{"key":"1564_CR100","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.3390\/nu16172947","volume":"16","author":"L Cheng","year":"2024","unstructured":"Cheng, L., Shi, C., Li, X. & Matsui, T. Impact of peptide transport and memory function in the brain. Nutrients 16, 2947, https:\/\/doi.org\/10.3390\/nu16172947 (2024).","journal-title":"Nutrients"},{"key":"1564_CR101","doi-asserted-by":"publisher","first-page":"13236","DOI":"10.1021\/acsomega.4c10849","volume":"10","author":"A Anton-Fernandez","year":"2025","unstructured":"Anton-Fernandez, A. et al. Peptide family promotes brain cell rejuvenation and improved cognition through peripheral delivery. ACS Omega 10, 13236\u201313250 (2025).","journal-title":"ACS Omega"},{"key":"1564_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12987-018-0097-2","volume":"15","author":"ME Noumbissi","year":"2018","unstructured":"Noumbissi, M. E., Galasso, B. & Stins, M. F. Brain vascular heterogeneity: implications for disease pathogenesis and design of in vitro blood\u2013brain barrier models. Fluids Barriers CNS 15, 1\u201312 (2018).","journal-title":"Fluids Barriers CNS"},{"key":"1564_CR103","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/bs.apha.2014.06.004","volume":"71","author":"TS Salameh","year":"2014","unstructured":"Salameh, T. S. & Banks, W. A. Delivery of therapeutic peptides and proteins to the CNS. Adv. Pharm. 71, 277\u2013299 (2014).","journal-title":"Adv. Pharm."},{"key":"1564_CR104","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/S0196-9781(97)00242-8","volume":"18","author":"RD Egleton","year":"1997","unstructured":"Egleton, R. D. & Davis, T. P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 18, 1431\u20131439 (1997).","journal-title":"Peptides"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01564-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:03:02Z","timestamp":1765296182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01564-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":104,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01564-4","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.-J.L. is a founder and CEO of Neuramedy Co. Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}